ProCE Banner Activity

DIAMOND: High Virologic Suppression Rates Achieved Following Rapid Initiation of DRV/COBI/FTC/TAF Regardless of Baseline HIV-1 RNA Level or CD4+ Cell Count

Slideset Download
Conference Coverage
No patient met criteria for protocol-defined virologic failure or discontinued for lack of efficacy through Week 48.

Released: October 29, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare